The first international symposium of Prestige Biopharma IDC was a meaningful event that shared advanced biopharmaceutical technologies and platform development achievements while discussing the possibilities of collaboration and innovation.On the first day, presentations covered topics such as disease modulation, new drug development strategies, and immune-modulating virus therapies, offering insights into the future of advanced biotechnologies.On the second day, discussions focused on global biopharma collaboration and innovation cases, strategies for supporting biotech startups, and R&D cooperation achievements, with panel discussions presenting growth directions and collaboration strategies for the biopharma industry.This symposium served as an opportunity to foster networking and information exchange among experts, solidifying Prestige Biopharma IDC's vision to become a global innovation hub in the biopharma industry.

Prestige Biopharma Group has taken its first step toward becoming a global innovation hub in the biopharma industry with the opening ceremony of its R&D control tower, the Innovation Drug Center (IDC).With its cutting-edge research platform and global network, IDC is dedicated to the development of antibody therapeutics and biosimilars for the treatment of intractable diseases, embodying the vision of "Innovation for Life."The international symposium held alongside the opening ceremony provided an opportunity to share achievements in biopharmaceutical technologies and platform development, while exploring the possibilities of collaboration and innovation.Moving forward, IDC aims to lead the global biopharma industry and establish itself as a world-class biopharma cluster.We kindly ask for your continued interest and support in the journey of the Innovation Drug Center.

BIO USA 2024 has opened today in the United States.Prestige Biopharma Group is continuing with over 30 meetings on the first day.All employees are committed to doing their best to achieve successful outcomes.

Prestige Biologics, a Contract Development and Manufacturing Organization (CDMO) specializing in biopharmaceuticals, has signed a biologics manufacturing deal with Celltrion, a developer of the world's first monoclonal antibody biosimilar.The 5-year agreement will establish Prestige Biologics as a leading biologics manufacturing company in Osong, one of the biggest biomedical hubs in South Korea. This collaboration with Celltrion underscores Prestige Biologics' expertise in biopharmaceuticals, solidifying its prominent position in the rapidly evolving field of biologics manufacturing."We are pleased to announce our partnership with Celltrion,” stated Jae Young Yang, Director of the Business Development (BD) Center. “This contract holds a significant meaning as it marks the official beginning of Prestige Biologics’ CDMO business. This proven track record with Celltrion will pave the way for future contracts with global biologics clients.”Prestige Biologics is a biopharmaceutical CDEMO (Contract Development Engineering and Manufacturing Organization) that operates production facilities based in South Korea. With a manufacturing capacity of 154,000 litres, Prestige Biologics stands as one of the top 10 global CDMO companies working with animal cell culture.Celltrion is a leading biopharmaceutical company dedicated to developing innovative therapeutics that improve patients’ health and well-being. The company’s therapeutic solutions include monoclonal antibody biosimilars such as Remsima(Infliximab), Herzuma(Trastuzumab), Truxima(Rituximab), Remsima SC(Infliximab), Yuflyma(Adalimumab), and Vegzelma(Bevacizumab).

Prestige Biologics enters into MoU with Aurigene Pharmaceutical Services Limited to explore collaboration in the global biologics CDMO marketPrestige Biologics, a Contract Development and Manufacturing Organization (CDMO) specializing in biopharmaceuticals, announced the establishment of a strategic partnership with Aurigene Pharmaceutical Services Limited (APSL), a wholly owned step-down subsidiary company of Dr. Reddy’s Laboratories Limited, through the signing of a non-binding Memorandum of Understanding (MoU). The MoU, which is subject to a Definitive Agreement, will oversee collaborative efforts between Prestige Biologics and APSL to bring in a comprehensive set of services and capabilities towards meeting the CDMO needs of biologics-focused companies. “We are delighted to announce our strategic partnership with Aurigene Pharmaceutical Services Limited,” stated Duk Hoon Hyun, CEO of Prestige Biologics. “Prestige Biologics’ global prominence in the CDMO market, coupled with Aurigene’s pharmaceutical expertise in R&D services, will create an end-to-end service capability in the Biologics CRDMO segment through this collaboration, offering cell line development to large-scale manufacturing services for global Biologics customers.”Aurigene Pharmaceutical Services Limited is a Contract Research, Development and Manufacturing Organization (CRDMO) with end-to-end capabilities across drug discovery, development, and manufacturing of small and large molecules. Dr. Reddy’s Laboratories Limited, the parent company of APSL, is a global pharmaceutical company, founded in 1984, with four decades of expertise in pharmaceutical development, and a global commercial network. Prestige Biologics operates production facilities based in South Korea, with a manufacturing capacity of 154,000 litres, making Prestige Biologics one of the top 10 global CDMO companies working with animal cell culture.

On Friday, June 23rd, Prestige Biologics welcomed guests. As part of the Global Bio Human Resource Training Hub Program supported by the World Health Organization (WHO), more than 60 biopharmaceutical industry experts from developing countries visited Prestige Biologics Osong Campus.This exchange program for technical education, conducted in association with WHO from June 19th to 30th, aims to develop the capabilities of professional manufacturing personnel who have been engaged in the biopharmaceutical industry for more than 6 years in Low, Middle Income Countries (LMIC). will contribute to strengthening It is expected to increase understanding of Korea's outstanding biopharmaceutical development and production capabilities and help develop the biopharmaceutical industry in low- and middle-income countries. Within the biopharmaceutical industry for the past few years, there has been a lively discussion on bioequity, which is the free access to the benefits of biopharmaceuticals regardless of national or individual income levels. In order to achieve meaningful results in Bio Equity, which is set as an important future goal by the bio industry and medical policy organizations in each region, it is necessary to secure a stable supply chain, biopharmaceutical production capacity, and various competitions among biopharmaceuticals. In this environment, it is also important that biopharmaceutical CDMO service companies should make efforts to improve production efficiency and continuously develop production technologies that provide higher yields.Various questions and answers are being conducted with the participants through the comprehensive control monitor, which shows the status of the entire production facility.The World Health Organization (WHO) and the Ministry of Health and Welfare of the Republic of Korea are operating the first global biomanpower training hub (GTH-B) to build vaccine and biopharmaceutical manufacturing capabilities in LMIC countries. In the global biopharmaceutical industry, humans contribute to life in many aspects. This is not limited to the development and production of biopharmaceuticals, but it is necessary to consider bio research and new drugs that are continuously entering the stage of commercial production, where regulations and systems in major countries are rapidly changing. In terms of institutional aspects, Bio Equity also has an aspect that can be supplied to patients more quickly and at the right time when policy-making institutions and academics in major countries have sufficient understanding. In order to strengthen this understanding and expand greater consensus, this event in collaboration between WHO and the Korean Ministry of Health and Welfare has a very important meaning.Prestige Biologics' main production capacity and secured production facilities are introduced to public officials from LMIC countries, academia and industry participants.Prestige Biologics introduced its production facilities, QC and PD facilities of its own production facilities, Plants 1 and 4, to officials from the Ministry of Food and Drug Safety, pharmaceutical companies, and universities in developing countries, and explained the production process. In particular, Plant 1 showed great interest in a full single-use system based on a single-use bioreactor with a capacity of 2,000 liters. Not only did it flexibly respond to customer needs with easy equipment arrangement or process and product changes, but also the fact that contamination was minimized through the use of disposable bags attracted the attention of the participants. Factory 4 introduced ‘ALITA Smart BioFactory’, which combines single use and stainless steel, focusing on the digital automation of the production process.Participants showing high interest in the description of the key analytical tests for production.In order to respond to the demand for flexibility in production capacity and diversification of the biopharmaceutical industry that is currently underway, Prestige BioLogics has optimized and strategically optimized four biopharmaceutical production plants in two campuses within the Osong bio cluster. All facilities are strategically organized around a 2,000 liter single use bioreactor. The 2,000 liter single-use bioreactor, which was strategically adopted as a production system that can respond most flexibly to the needs of commercial production of various scales, is now also a production facility strategy that is being reviewed as important by other countries and companies. Prestige Biologics has already successfully carried out process development and commercial production of biosimilars and new antibody drugs using the leading production system already secured. Through this, we are accumulating biopharmaceutical production technology through 2,000 liter single-use bioreactor and hybrid system, and making continuous improvements.In the ‘2023 Vaccine/Biopharmaceutical Quality Management Basic Training (GxP Course)’, participants listen to the company introduction and take a commemorative photo (CEO in the middle).An official from a major pharmaceutical company who participated in the tour said, “The tour to the manufacturing process of Prestige Biologics’ state-of-the-art facilities was an important time to gain insights on the overall biopharmaceutical production process. It was a valuable opportunity to see and learn not only the GMP of Korean government agencies, but also the GMP approval for biopharmaceutical manufacturing facilities in EU countries.” We will take the lead in improving biopharmaceutical production capacity.”